Brentuximab Vedotin in Refractory or Relapsed Peripheral T-cell Lymphomas: the French Named Patient Program Experience in 56 Patients

Overview

Journal Haematologica

Specialty Hematology

Date 2015 Dec 26

PMID 26703966

Citations 11

Authors

Mathilde Lamarque

Celine Bossard

Adrien Contejean

Pauline Brice

Marie Parrens

Steven Le Gouill

Josette Briere

Reda Bouabdallah

Danielle Canioni

Herve Tilly

Brigitte Bouchindhomme

Emmanuel Bachy

Richard Delarue

Corinne Haioun

Philippe Gaulard

Affiliations

Soon will be listed here.

Citing Articles

Recent Advances in Understanding the Clinical Responses of Brentuximab Vedotin in Lymphoma and the Correlation with CD30 Expression.

Chen W, Zhang Z Onco Targets Ther. 2025; 18():1-14.

PMID: 39802262 PMC: 11720807. DOI: 10.2147/OTT.S487088.

Case Report: A recurrent case of ALK-ALCL after autologous transplantation was successfully treated with BV + a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome with the addition of chidamide maintenance therapy.

Shang Z, Zhang Q, Liu W, Wu J, Zhang Y, Xiao Y Front Oncol. 2023; 13:1242552.

PMID: 37849796 PMC: 10577165. DOI: 10.3389/fonc.2023.1242552.

Evans Syndrome as a Possible Complication of Brentuximab Vedotin Therapy for Peripheral T Cell Lymphoma.

Irimia R, Barbu S, Popa C, Badelita S Hematol Rep. 2023; 15(1):220-224.

PMID: 36975736 PMC: 10048708. DOI: 10.3390/hematolrep15010023.

Estimating long-term progression-free and overall survival in patients with peripheral T-cell lymphoma: A US population-based oncology simulation model based on 5-year results from the ECHELON-2 trial.

Burke J, Yu K, Mordi U, Bloudek B, Liu N, Phillips T J Manag Care Spec Pharm. 2023; 29(3):314-323.

PMID: 36840956 PMC: 10387925. DOI: 10.18553/jmcp.2023.29.3.314.

Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.

Prince H, Hutchings M, Domingo-Domenech E, Eichenauer D, Advani R Ann Hematol. 2022; 102(1):13-29.

PMID: 36512081 PMC: 9807535. DOI: 10.1007/s00277-022-05054-9.

References

Bossard C, Dobay M, Parrens M, Lamant L, Missiaglia E, Haioun C . Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. Blood. 2014; 124(19):2983-6. DOI: 10.1182/blood-2014-07-584953. View

Illidge T, Bouabdallah R, Chen R, Gopal A, Moskowitz C, Ramchandren R . Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leuk Lymphoma. 2014; 56(3):703-10. DOI: 10.3109/10428194.2014.930852. View

Horwitz S, Advani R, Bartlett N, Jacobsen E, Sharman J, OConnor O . Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood. 2014; 123(20):3095-100. PMC: 4425442. DOI: 10.1182/blood-2013-12-542142. View

Sabattini E, Pizzi M, Tabanelli V, Baldin P, Sacchetti C, Agostinelli C . CD30 expression in peripheral T-cell lymphomas. Haematologica. 2013; 98(8):e81-2. PMC: 3729886. DOI: 10.3324/haematol.2013.084913. View

Vose J, Armitage J, Weisenburger D . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26(25):4124-30. DOI: 10.1200/JCO.2008.16.4558. View

Savage K, Lee Harris N, Vose J, Ullrich F, Jaffe E, Connors J . ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008; 111(12):5496-504. DOI: 10.1182/blood-2008-01-134270. View

Kim Y, Tavallaee M, Sundram U, Salva K, Wood G, Li S . Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol. 2015; 33(32):3750-8. PMC: 5089160. DOI: 10.1200/JCO.2014.60.3969. View

Pro B, Advani R, Brice P, Bartlett N, Rosenblatt J, Illidge T . Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30(18):2190-6. DOI: 10.1200/JCO.2011.38.0402. View

Jacobsen E, Sharman J, Oki Y, Advani R, Winter J, Bello C . Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015; 125(9):1394-402. DOI: 10.1182/blood-2014-09-598763. View

10.

Duvic M, Tetzlaff M, Gangar P, Clos A, Sui D, Talpur R . Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol. 2015; 33(32):3759-65. PMC: 4737859. DOI: 10.1200/JCO.2014.60.3787. View

11.

Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn L . Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013; 31(16):1970-6. DOI: 10.1200/JCO.2012.44.7524. View